Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CRDO +32.8%, CNM +8.5%, T +3.3% (guidance), SJM +1.3% (closing of transaction to divest Voortman business; updates FY25 revenue guidance), DCI +1.1%, ENB +0.8% (guidance), AMAT +0.5% (guidance)
Other news:
- JANX +73% (doses selected for Phase 1b trials)
- CHRS +32.8% (enters into asset purchase agreement with Intas Pharmaceuticals for the divestiture of the UDENYCA franchise for up to $558.4 mln)
- CRBP +5.9% (grants fast track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer)
- TERN +5.9% (Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia)
- SPIR +4.7% (appoints Theresa Condor as CEO and taps aerospace industry veterans for executive team)
- INGM +4.3% (restructuring and reducing headcount)
- RYN +4.1% (special dividend)
- JSPR +3.8% (first patient dosed in ETESIAN Clinical Study)
- RYTM +3.2% (announces Imcivree receives expanded marketing authorization in the United Kingdom for treatment of obesity and control of hunger in patients)
- IONQ +3.1% (unveils quantum OS)
- KELYA +3% (approves share repurchase program authorizing purchase up to $50 million of its Class A common stock)
- COMP +2.8% (partnering with multiple entities)
- IMCR +2.5% (announces reimbursement agreement in England for KIMMTRAK)
- PVBC +2.4% (adopts 5% repurchase plan)
- JOBY +2.3% (CFO to resign)
- RNAC +2.2% (updated results in participants with myasthenia gravis and outlines design of planned Phase 3 Trial)
- BWMN +1.7% (increases repurchase plan)
- TELO +1.4% (announced compelling preclinical results demonstrating the ability of its licensed molecule, Telomir-1, to reverse insulin resistance to near pre-diabetes levels in a zebrafish model of Type 2 diabetes mellitus)
- VEON +1.3% (In an Open Letter to VEON Investors, VEON Group CEO Welcomes the Unfreezing of VEON's Corporate Rights on Kyivstar)
- HAE +1.2% (enters sale of whole blood assets to GVS, S.p.A)
- MIR +1.2% (to detail financial targets and long-term strategy at today's investor day; will also announce a share repurchase program for up to $100 million of the currently outstanding shares of the company's Class A common stock)
- PCG +1.1% (prices common stock and mandatory convertible Preferred Stock offerings)
- PTLO +1% (appoints new COO)
- WPP +1% (completed the transaction to sell its majority stake in FGS Global to Kite Bidco)